<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e53cf92d-28c4-40c2-8974-53faa91263d4,g:96be954d-ed6d-4a72-bf49-5d7dea5c5569-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhvn-20230630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd518555-21e7-4907-bfbd-4367009dfa82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3ce0066d-ffb4-44ab-8caa-2af29622e944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd518555-21e7-4907-bfbd-4367009dfa82" xlink:to="loc_us-gaap_Liabilities_3ce0066d-ffb4-44ab-8caa-2af29622e944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8848da19-a667-4c7f-92f2-b5ab041fad8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd518555-21e7-4907-bfbd-4367009dfa82" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8848da19-a667-4c7f-92f2-b5ab041fad8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a57b08ce-8034-49ce-be3c-ff0f48e9064e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd518555-21e7-4907-bfbd-4367009dfa82" xlink:to="loc_us-gaap_StockholdersEquity_a57b08ce-8034-49ce-be3c-ff0f48e9064e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3dc122af-8dc9-47cd-bcfc-60e5a5633c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ffed0e3a-4268-484c-a90d-faee76dd37d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3dc122af-8dc9-47cd-bcfc-60e5a5633c9b" xlink:to="loc_us-gaap_LiabilitiesCurrent_ffed0e3a-4268-484c-a90d-faee76dd37d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d4b692b5-7b5d-4f79-bf75-b64d62a3eede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3dc122af-8dc9-47cd-bcfc-60e5a5633c9b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d4b692b5-7b5d-4f79-bf75-b64d62a3eede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_55b43a9f-ecb0-425a-8a34-75e713c05641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3dc122af-8dc9-47cd-bcfc-60e5a5633c9b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_55b43a9f-ecb0-425a-8a34-75e713c05641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5313d1e1-998e-4231-bb01-ea69c6338fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3c0bb59d-879f-4377-b24f-eff183fefa00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5313d1e1-998e-4231-bb01-ea69c6338fc7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3c0bb59d-879f-4377-b24f-eff183fefa00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d90cb25d-b565-4000-8453-37b758982c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5313d1e1-998e-4231-bb01-ea69c6338fc7" xlink:to="loc_us-gaap_AccountsPayableCurrent_d90cb25d-b565-4000-8453-37b758982c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_DueToFormerParentCurrent_82ee569d-b817-406b-b659-f903c39bb71d" xlink:href="bhvn-20230630.xsd#bhvn_DueToFormerParentCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5313d1e1-998e-4231-bb01-ea69c6338fc7" xlink:to="loc_bhvn_DueToFormerParentCurrent_82ee569d-b817-406b-b659-f903c39bb71d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9a52ea76-b695-4fb0-9d4a-472f8d261e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ec76fe49-51c9-4d75-917c-8003c42e14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a52ea76-b695-4fb0-9d4a-472f8d261e2c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ec76fe49-51c9-4d75-917c-8003c42e14b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ec6abbe1-d26f-4096-b1fd-95ffc0ac50dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a52ea76-b695-4fb0-9d4a-472f8d261e2c" xlink:to="loc_us-gaap_RestrictedCashCurrent_ec6abbe1-d26f-4096-b1fd-95ffc0ac50dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_94f153d4-de9c-43fe-b1de-ba006ba8fcda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a52ea76-b695-4fb0-9d4a-472f8d261e2c" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_94f153d4-de9c-43fe-b1de-ba006ba8fcda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3975838-3686-450d-9b5f-5bf50ce67fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a52ea76-b695-4fb0-9d4a-472f8d261e2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3975838-3686-450d-9b5f-5bf50ce67fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4832add0-47b7-4d88-95ab-ef2f109c0cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a52ea76-b695-4fb0-9d4a-472f8d261e2c" xlink:to="loc_us-gaap_OtherAssetsCurrent_4832add0-47b7-4d88-95ab-ef2f109c0cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_db7fe5cf-65dd-4553-a1e3-5cf51a413deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a52ea76-b695-4fb0-9d4a-472f8d261e2c" xlink:to="loc_us-gaap_IncomeTaxesReceivable_db7fe5cf-65dd-4553-a1e3-5cf51a413deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45cfb26a-2ff9-43fb-acd7-fcceaf02a899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_42e29134-1036-49d4-a964-f5fd25f9a966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_45cfb26a-2ff9-43fb-acd7-fcceaf02a899" xlink:to="loc_us-gaap_PreferredStockValue_42e29134-1036-49d4-a964-f5fd25f9a966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20cdf191-bdf0-4cd8-a05f-f7c0c5b51135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_45cfb26a-2ff9-43fb-acd7-fcceaf02a899" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20cdf191-bdf0-4cd8-a05f-f7c0c5b51135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4eddfaed-fc45-4b6f-bb63-09a125f39ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_45cfb26a-2ff9-43fb-acd7-fcceaf02a899" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4eddfaed-fc45-4b6f-bb63-09a125f39ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8806b5ab-3caa-44a8-807d-c97b96aa282e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_45cfb26a-2ff9-43fb-acd7-fcceaf02a899" xlink:to="loc_us-gaap_CommonStockValue_8806b5ab-3caa-44a8-807d-c97b96aa282e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f075283-2a56-4d5f-a015-975ba846d744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_45cfb26a-2ff9-43fb-acd7-fcceaf02a899" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f075283-2a56-4d5f-a015-975ba846d744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_edfaa9e9-6a36-46d1-81db-ef1340d18bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_51367097-418b-4351-b4d1-a058760d23e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edfaa9e9-6a36-46d1-81db-ef1340d18bd9" xlink:to="loc_us-gaap_AssetsCurrent_51367097-418b-4351-b4d1-a058760d23e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_67ec794a-f52b-412a-ac39-ce0fbdf9b380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edfaa9e9-6a36-46d1-81db-ef1340d18bd9" xlink:to="loc_us-gaap_Goodwill_67ec794a-f52b-412a-ac39-ce0fbdf9b380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_82dab01a-ec90-4a94-bca0-9813948d6975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edfaa9e9-6a36-46d1-81db-ef1340d18bd9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_82dab01a-ec90-4a94-bca0-9813948d6975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9059637b-fdb5-4518-a747-a2c25b465ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edfaa9e9-6a36-46d1-81db-ef1340d18bd9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9059637b-fdb5-4518-a747-a2c25b465ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6a649e73-cd8d-4f33-bb50-bc4bce5e4369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edfaa9e9-6a36-46d1-81db-ef1340d18bd9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6a649e73-cd8d-4f33-bb50-bc4bce5e4369" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhvn-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4a2cb08e-1dec-4411-9816-9155f11b19a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cc4a8e40-b645-4824-a6a4-a21cf47859b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4a2cb08e-1dec-4411-9816-9155f11b19a8" xlink:to="loc_us-gaap_CostsAndExpenses_cc4a8e40-b645-4824-a6a4-a21cf47859b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_074a5947-23b2-4505-a1da-5473bfb0c789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1d6149e4-31c9-4a13-b719-240dfe08ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_074a5947-23b2-4505-a1da-5473bfb0c789" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1d6149e4-31c9-4a13-b719-240dfe08ca81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2486828e-9f21-4976-a72d-2cefb9eaa7df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2c73b084-20f6-4186-908c-0477a30c2740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2486828e-9f21-4976-a72d-2cefb9eaa7df" xlink:to="loc_us-gaap_OperatingIncomeLoss_2c73b084-20f6-4186-908c-0477a30c2740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_db0b2282-e512-4ecc-93e2-88de88801ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2486828e-9f21-4976-a72d-2cefb9eaa7df" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_db0b2282-e512-4ecc-93e2-88de88801ad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b1713743-b304-43dc-ba1b-949402fdafa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b30176db-2528-4c41-a3e8-3cef77dfdc67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b1713743-b304-43dc-ba1b-949402fdafa1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b30176db-2528-4c41-a3e8-3cef77dfdc67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0418ebe4-1e27-4ccb-8f10-db46f4725275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b1713743-b304-43dc-ba1b-949402fdafa1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0418ebe4-1e27-4ccb-8f10-db46f4725275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4723003-a04f-4b34-817d-7da40863e7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c94bea88-0d6f-49c9-93fb-23fb98998fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4723003-a04f-4b34-817d-7da40863e7d2" xlink:to="loc_us-gaap_NetIncomeLoss_c94bea88-0d6f-49c9-93fb-23fb98998fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_74ba6c11-b458-4c15-be5c-96c286ed7b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4723003-a04f-4b34-817d-7da40863e7d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_74ba6c11-b458-4c15-be5c-96c286ed7b0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2e06e8fb-acf1-4204-ae0f-b45a45d8c1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_53f68b1f-b7dd-4c52-b04e-7b6e462df924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2e06e8fb-acf1-4204-ae0f-b45a45d8c1f8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_53f68b1f-b7dd-4c52-b04e-7b6e462df924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_67804c39-5541-47d4-8e4a-ac4eb64e2f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2e06e8fb-acf1-4204-ae0f-b45a45d8c1f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_67804c39-5541-47d4-8e4a-ac4eb64e2f0a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhvn-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a659ef8f-bc13-4e28-a957-ec41166fe3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a10705f-6160-4375-88f1-fcd927c31e73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a659ef8f-bc13-4e28-a957-ec41166fe3a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a10705f-6160-4375-88f1-fcd927c31e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dab141ef-051a-4fa9-b3d8-22a50c4a21fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a659ef8f-bc13-4e28-a957-ec41166fe3a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dab141ef-051a-4fa9-b3d8-22a50c4a21fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea3beb62-6a0d-466a-8307-8e1adbc0793a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a659ef8f-bc13-4e28-a957-ec41166fe3a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea3beb62-6a0d-466a-8307-8e1adbc0793a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba67f57b-2902-4f0d-989d-b38bc2997d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a659ef8f-bc13-4e28-a957-ec41166fe3a9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba67f57b-2902-4f0d-989d-b38bc2997d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9031f10d-4a33-48d2-b6b7-6014fd61bb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b536a94d-77f8-4f88-9b4e-d8c72b3d42f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9031f10d-4a33-48d2-b6b7-6014fd61bb6b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b536a94d-77f8-4f88-9b4e-d8c72b3d42f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_47563b04-295e-49fc-933a-751c3a71ad34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9031f10d-4a33-48d2-b6b7-6014fd61bb6b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_47563b04-295e-49fc-933a-751c3a71ad34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d21399c5-4d9d-4039-bddb-0c8a296211b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9031f10d-4a33-48d2-b6b7-6014fd61bb6b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d21399c5-4d9d-4039-bddb-0c8a296211b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b6136ce3-3258-427e-927c-8986e88285a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9031f10d-4a33-48d2-b6b7-6014fd61bb6b" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b6136ce3-3258-427e-927c-8986e88285a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_486118c0-a54b-4a96-87fc-d5e2abe30da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_486118c0-a54b-4a96-87fc-d5e2abe30da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d3b46f27-304c-4e63-8df2-9b005076dd02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d3b46f27-304c-4e63-8df2-9b005076dd02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6c6c575c-1359-4622-90a5-48ad8aea18ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6c6c575c-1359-4622-90a5-48ad8aea18ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_edab74ba-d3b8-4315-bf02-3286e05dbc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_NetIncomeLoss_edab74ba-d3b8-4315-bf02-3286e05dbc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15c655bd-46f0-4c16-b5b1-5fa39564612e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_ShareBasedCompensation_15c655bd-46f0-4c16-b5b1-5fa39564612e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8feff0ce-e954-428a-9dd5-7318decd4445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8feff0ce-e954-428a-9dd5-7318decd4445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_99fa8dd2-4256-4c38-ab46-fce85fd41843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_99fa8dd2-4256-4c38-ab46-fce85fd41843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ProceedsFromAcquisitionOfResearchAndDevelopmentAsset_3bc15957-2257-4ddc-8608-0b365095cce9" xlink:href="bhvn-20230630.xsd#bhvn_ProceedsFromAcquisitionOfResearchAndDevelopmentAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_bhvn_ProceedsFromAcquisitionOfResearchAndDevelopmentAsset_3bc15957-2257-4ddc-8608-0b365095cce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_38082839-a752-401e-90c1-e5cc3c13af92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e28453-03fa-4c9c-9d3c-967c6bed1755" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_38082839-a752-401e-90c1-e5cc3c13af92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7105b28-25f3-496f-8f85-fb9c3c9ab207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6a851e02-e1f0-44da-9805-a5124d5594a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7105b28-25f3-496f-8f85-fb9c3c9ab207" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6a851e02-e1f0-44da-9805-a5124d5594a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_5621cd85-61db-4719-8ba4-d5ba889cb7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7105b28-25f3-496f-8f85-fb9c3c9ab207" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_5621cd85-61db-4719-8ba4-d5ba889cb7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ChangeInRestrictedCashHeldOnBehalfOfFormerParentFinancingActivities_2364e97a-107e-45ea-b1ab-724484ebc92a" xlink:href="bhvn-20230630.xsd#bhvn_ChangeInRestrictedCashHeldOnBehalfOfFormerParentFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7105b28-25f3-496f-8f85-fb9c3c9ab207" xlink:to="loc_bhvn_ChangeInRestrictedCashHeldOnBehalfOfFormerParentFinancingActivities_2364e97a-107e-45ea-b1ab-724484ebc92a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_2799a38e-1760-4634-81bd-15444de54fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_17ca1c6a-c05a-4cd4-939f-5a7aac2c8cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_2799a38e-1760-4634-81bd-15444de54fed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_17ca1c6a-c05a-4cd4-939f-5a7aac2c8cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_86cfda5e-0a6c-4a05-b7b0-ad272ba83915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_2799a38e-1760-4634-81bd-15444de54fed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_86cfda5e-0a6c-4a05-b7b0-ad272ba83915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eeb9b88a-51b9-49ce-b723-8b62c4117984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_2799a38e-1760-4634-81bd-15444de54fed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eeb9b88a-51b9-49ce-b723-8b62c4117984" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#MarketableSecuritiesContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1f725ff-73b7-4139-a739-23453b1e402e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_03d6bf92-471c-42e7-9d92-03ad5b159f69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1f725ff-73b7-4139-a739-23453b1e402e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_03d6bf92-471c-42e7-9d92-03ad5b159f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1ad7f251-2f5c-400a-9396-2c01ce112717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_961ef065-4a83-4777-afb2-6e31006204d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1ad7f251-2f5c-400a-9396-2c01ce112717" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_961ef065-4a83-4777-afb2-6e31006204d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#MarketableSecuritiesNetInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_InvestmentIncomeExcludingRealizedGainLoss_14bf0681-df65-43ef-97ae-a5cd87589dd0" xlink:href="bhvn-20230630.xsd#bhvn_InvestmentIncomeExcludingRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_fe6cd99e-f0d3-423a-88c3-dd0b5099043a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bhvn_InvestmentIncomeExcludingRealizedGainLoss_14bf0681-df65-43ef-97ae-a5cd87589dd0" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_fe6cd99e-f0d3-423a-88c3-dd0b5099043a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_6066abc2-5044-45f6-94d3-a8baee35e14d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bhvn_InvestmentIncomeExcludingRealizedGainLoss_14bf0681-df65-43ef-97ae-a5cd87589dd0" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_6066abc2-5044-45f6-94d3-a8baee35e14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_acabd736-18ac-44bb-b207-f49eb72bcaef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_InvestmentIncomeExcludingRealizedGainLoss_0e7a7d32-7ad2-43e5-a7ee-bf5c287f7805" xlink:href="bhvn-20230630.xsd#bhvn_InvestmentIncomeExcludingRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_acabd736-18ac-44bb-b207-f49eb72bcaef" xlink:to="loc_bhvn_InvestmentIncomeExcludingRealizedGainLoss_0e7a7d32-7ad2-43e5-a7ee-bf5c287f7805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a60192e5-705b-4190-858e-3d87a3bb8867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_acabd736-18ac-44bb-b207-f49eb72bcaef" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a60192e5-705b-4190-858e-3d87a3bb8867" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a39418ad-d4b6-4518-b2a3-83edd7f868aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6d74ef12-3047-4ff2-89b5-84aa90edd226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a39418ad-d4b6-4518-b2a3-83edd7f868aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6d74ef12-3047-4ff2-89b5-84aa90edd226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_0a1016fb-2d88-420f-b821-5d4abab69ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a39418ad-d4b6-4518-b2a3-83edd7f868aa" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_0a1016fb-2d88-420f-b821-5d4abab69ade" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3f63fb34-7d20-40d3-ae96-422bb5015923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_507e7742-a8a0-4e2a-a518-62b124ac7699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3f63fb34-7d20-40d3-ae96-422bb5015923" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_507e7742-a8a0-4e2a-a518-62b124ac7699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c7414bb2-ba5b-4f1a-99e1-a280166d0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3f63fb34-7d20-40d3-ae96-422bb5015923" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c7414bb2-ba5b-4f1a-99e1-a280166d0c1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#BalanceSheetComponentsOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ff26bad8-23fa-4dce-aca6-1e897001ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_66df3ca6-ecbf-4222-aeea-20f87838da4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_ff26bad8-23fa-4dce-aca6-1e897001ff97" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_66df3ca6-ecbf-4222-aeea-20f87838da4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_a85414c2-0365-4cd7-bad2-bd7177ccc112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_ff26bad8-23fa-4dce-aca6-1e897001ff97" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_a85414c2-0365-4cd7-bad2-bd7177ccc112" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2c59d16a-6992-4066-a676-0b976c197695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9be23466-57ca-4af9-9461-a08d06bb2986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2c59d16a-6992-4066-a676-0b976c197695" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9be23466-57ca-4af9-9461-a08d06bb2986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedClinicalTrialCostsCurrent_151d3d45-5524-4528-84b9-220bf350a995" xlink:href="bhvn-20230630.xsd#bhvn_AccruedClinicalTrialCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2c59d16a-6992-4066-a676-0b976c197695" xlink:to="loc_bhvn_AccruedClinicalTrialCostsCurrent_151d3d45-5524-4528-84b9-220bf350a995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ed7be524-8b6e-4bd4-8270-9188ea931f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2c59d16a-6992-4066-a676-0b976c197695" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ed7be524-8b6e-4bd4-8270-9188ea931f31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="bhvn-20230630.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c342f1f-7eb6-4901-89b9-b1f52473dba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_9077ef9c-3dd1-4bbf-98f7-606f51877f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c342f1f-7eb6-4901-89b9-b1f52473dba6" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_9077ef9c-3dd1-4bbf-98f7-606f51877f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_d2302ed0-5a12-419f-b0ab-4d417e4c8442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c342f1f-7eb6-4901-89b9-b1f52473dba6" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_d2302ed0-5a12-419f-b0ab-4d417e4c8442" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
